A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS
The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed. La présente inve...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | CHAPRON, CHRISTOPHER CHYUNG, YUNG WEBSTER, MICAH T LONG, KIMBERLY FLIER, JEFFREY S NOMIKOS, GEORGE |
| description | The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed.
La présente invention concerne le traitement de troubles métaboliques, tels que le syndrome métabolique, l'obésité et le diabète de type 2. L'invention concerne des polythérapies et des polythérapies qui comprennent un inhibiteur de la voie de passage de la myostatine, utilisé conjointement avec un activateur de la voie de passage du GLP-1. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3221555A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3221555A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3221555A13</originalsourceid><addsrcrecordid>eNqNjEEKgzAURN10Udre4V_AhYoH-MZoPphEkt-KKxFJV6UV7P1phNJ1F8MMzJs5JhuCHq1nZDLQI6sBRyCjqCK2LiYQVldkYm8NDMQKENquT7MfjYLphjvdRF293Ffs5H7ZgpaMle1IQE3eulo6f04O9_mxhcvXTwk0koVKw_qawrbOS3iG9ySwyPOsLEvMij-QD_vcN_g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS</title><source>esp@cenet</source><creator>CHAPRON, CHRISTOPHER ; CHYUNG, YUNG ; WEBSTER, MICAH T ; LONG, KIMBERLY ; FLIER, JEFFREY S ; NOMIKOS, GEORGE</creator><creatorcontrib>CHAPRON, CHRISTOPHER ; CHYUNG, YUNG ; WEBSTER, MICAH T ; LONG, KIMBERLY ; FLIER, JEFFREY S ; NOMIKOS, GEORGE</creatorcontrib><description>The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed.
La présente invention concerne le traitement de troubles métaboliques, tels que le syndrome métabolique, l'obésité et le diabète de type 2. L'invention concerne des polythérapies et des polythérapies qui comprennent un inhibiteur de la voie de passage de la myostatine, utilisé conjointement avec un activateur de la voie de passage du GLP-1.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221229&DB=EPODOC&CC=CA&NR=3221555A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,782,887,25571,76555</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221229&DB=EPODOC&CC=CA&NR=3221555A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHAPRON, CHRISTOPHER</creatorcontrib><creatorcontrib>CHYUNG, YUNG</creatorcontrib><creatorcontrib>WEBSTER, MICAH T</creatorcontrib><creatorcontrib>LONG, KIMBERLY</creatorcontrib><creatorcontrib>FLIER, JEFFREY S</creatorcontrib><creatorcontrib>NOMIKOS, GEORGE</creatorcontrib><title>A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS</title><description>The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed.
La présente invention concerne le traitement de troubles métaboliques, tels que le syndrome métabolique, l'obésité et le diabète de type 2. L'invention concerne des polythérapies et des polythérapies qui comprennent un inhibiteur de la voie de passage de la myostatine, utilisé conjointement avec un activateur de la voie de passage du GLP-1.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjEEKgzAURN10Udre4V_AhYoH-MZoPphEkt-KKxFJV6UV7P1phNJ1F8MMzJs5JhuCHq1nZDLQI6sBRyCjqCK2LiYQVldkYm8NDMQKENquT7MfjYLphjvdRF293Ffs5H7ZgpaMle1IQE3eulo6f04O9_mxhcvXTwk0koVKw_qawrbOS3iG9ySwyPOsLEvMij-QD_vcN_g</recordid><startdate>20221229</startdate><enddate>20221229</enddate><creator>CHAPRON, CHRISTOPHER</creator><creator>CHYUNG, YUNG</creator><creator>WEBSTER, MICAH T</creator><creator>LONG, KIMBERLY</creator><creator>FLIER, JEFFREY S</creator><creator>NOMIKOS, GEORGE</creator><scope>EVB</scope></search><sort><creationdate>20221229</creationdate><title>A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS</title><author>CHAPRON, CHRISTOPHER ; CHYUNG, YUNG ; WEBSTER, MICAH T ; LONG, KIMBERLY ; FLIER, JEFFREY S ; NOMIKOS, GEORGE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3221555A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>CHAPRON, CHRISTOPHER</creatorcontrib><creatorcontrib>CHYUNG, YUNG</creatorcontrib><creatorcontrib>WEBSTER, MICAH T</creatorcontrib><creatorcontrib>LONG, KIMBERLY</creatorcontrib><creatorcontrib>FLIER, JEFFREY S</creatorcontrib><creatorcontrib>NOMIKOS, GEORGE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHAPRON, CHRISTOPHER</au><au>CHYUNG, YUNG</au><au>WEBSTER, MICAH T</au><au>LONG, KIMBERLY</au><au>FLIER, JEFFREY S</au><au>NOMIKOS, GEORGE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS</title><date>2022-12-29</date><risdate>2022</risdate><abstract>The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed.
La présente invention concerne le traitement de troubles métaboliques, tels que le syndrome métabolique, l'obésité et le diabète de type 2. L'invention concerne des polythérapies et des polythérapies qui comprennent un inhibiteur de la voie de passage de la myostatine, utilisé conjointement avec un activateur de la voie de passage du GLP-1.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3221555A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T09%3A57%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHAPRON,%20CHRISTOPHER&rft.date=2022-12-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3221555A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |